BR112021023542A2 - Métodos para purificar anticorpos - Google Patents

Métodos para purificar anticorpos

Info

Publication number
BR112021023542A2
BR112021023542A2 BR112021023542A BR112021023542A BR112021023542A2 BR 112021023542 A2 BR112021023542 A2 BR 112021023542A2 BR 112021023542 A BR112021023542 A BR 112021023542A BR 112021023542 A BR112021023542 A BR 112021023542A BR 112021023542 A2 BR112021023542 A2 BR 112021023542A2
Authority
BR
Brazil
Prior art keywords
methods
recombinant antibody
purify antibodies
imidazole
antibody molecules
Prior art date
Application number
BR112021023542A
Other languages
English (en)
Inventor
William Phippen Curtis
Alan Watson Neil
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of BR112021023542A2 publication Critical patent/BR112021023542A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/26—Conditioning of the fluid carrier; Flow patterns
    • G01N30/38—Flow patterns
    • G01N2030/381—Flow patterns centrifugal chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

métodos para purificar anticorpos. a invenção se refere ao campo de fabricar moléculas de anticorpo recombinantes. em particular, métodos para purificar tais moléculas de anticorpo recombinantes são providas em que imidazol ou um análogo de imidazol é adicionado durante a elução da molécula de anticorpo recombinante a partir de uma resina de cromatografia por afinidade, tal como uma resina com base em proteína a.
BR112021023542A 2019-08-02 2020-07-30 Métodos para purificar anticorpos BR112021023542A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19189841 2019-08-02
PCT/EP2020/071533 WO2021023619A1 (en) 2019-08-02 2020-07-30 Methods for purifying antibodies

Publications (1)

Publication Number Publication Date
BR112021023542A2 true BR112021023542A2 (pt) 2022-03-22

Family

ID=67658409

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023542A BR112021023542A2 (pt) 2019-08-02 2020-07-30 Métodos para purificar anticorpos

Country Status (13)

Country Link
US (1) US20220280887A1 (pt)
EP (1) EP4007771A1 (pt)
JP (1) JP2022543187A (pt)
KR (1) KR20220039744A (pt)
CN (1) CN114401984A (pt)
AR (1) AR119546A1 (pt)
AU (1) AU2020326087A1 (pt)
BR (1) BR112021023542A2 (pt)
CA (1) CA3142610A1 (pt)
IL (1) IL289959A (pt)
MX (1) MX2022001349A (pt)
SG (1) SG11202112846RA (pt)
WO (1) WO2021023619A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7462762B2 (ja) * 2020-01-20 2024-04-05 ウーシー バイオロジクス アイルランド リミテッド アフィニティークロマトグラフィー用の新規な洗浄緩衝液

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726293A (en) * 1992-10-02 1998-03-10 The General Hospital Corporation Affinity purification methods involving imidazole elution
US20040063153A1 (en) * 2002-08-12 2004-04-01 Tomas Jelinek Method for isolation of protein complexes using affinity binding
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
ES2671347T3 (es) * 2010-06-21 2018-06-06 Kyowa Hakko Kirin Co., Ltd. Procedimiento para purificar una proteína que utiliza un aminoácido
EP2776466B1 (en) 2011-11-11 2017-08-23 UCB Biopharma SPRL Albumin binding antibodies and binding fragments thereof
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
JP6236948B2 (ja) * 2013-07-17 2017-11-29 東ソー株式会社 抗体精製用溶出液および当該溶出液を用いた抗体精製方法
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification

Also Published As

Publication number Publication date
KR20220039744A (ko) 2022-03-29
CA3142610A1 (en) 2021-02-11
EP4007771A1 (en) 2022-06-08
IL289959A (en) 2022-03-01
US20220280887A1 (en) 2022-09-08
JP2022543187A (ja) 2022-10-11
AU2020326087A1 (en) 2021-12-16
AR119546A1 (es) 2021-12-29
WO2021023619A1 (en) 2021-02-11
SG11202112846RA (en) 2021-12-30
MX2022001349A (es) 2022-03-25
CN114401984A (zh) 2022-04-26

Similar Documents

Publication Publication Date Title
BR112018000477A2 (pt) proteína de ligação de imunoglobulina não natural, composição, uso da proteína de ligação de ig não natural, método de purificação de afinidade de imunoglobulinas, método de geração de uma proteína de ligação de imunoglobulina não natural, molécula de ácido nucleico, vetor, célula hospedeira ou um hospedeiro não humano, e método para a produção de uma proteína de ligação de imunoglobulina não natural
MX2012012119A (es) Produccion de proteinas heteromultimericas.
BR112012024956A2 (pt) processo para a purificação de uma proteína de fator de crescimento
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
BR112018005573A2 (pt) ?polipeptídeos de ligação a cd3?
BRPI0814220A2 (pt) Purificação de fator viii usando uma resina multimodal ou de modo misto
BR112017019779A2 (pt) composto, e, composição farmacêutica
MX350962B (es) Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
CL2008002860A1 (es) Polipeptido; polinucleotido que lo codifica; vector y fago aislado que comprenda este polinucleotido; anticuerpo que se une a este polipeptido; molecula de fusion que comprende este polipeptido; celula huesped metanogena que comprende el vector; composicion farmaceutica que comprende el polinucleotido.
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
BR112020013197A8 (pt) Métodos de purificação de vírus adenoassociado
BR112014026359A2 (pt) produtos compósitos feitos com composições de agentes aglutinantes que incluem taninos e aldeídos multifuncionais
CY1114350T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
EA201100546A1 (ru) Полипептиды, вариабельные домены антител и антагонисты
BR112014004054A8 (pt) Composição de poliepóxido, composição de resina epóxi artigo de fabricação, método para a fabricação de uma composição de poliepóxido e método para a fabricação de uma resina epóxi
AR074015A1 (es) Purificacion de proteinas acidas utilizando cromatografia de hidroxiapatita ceramica
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
BR112014029566A2 (pt) agente terapêutico ou agente profilático para desordens cognitivas, anticorpo monoclonal, anticorpo para proteína tau fosforilada, e, peptídeo
BRPI0721238A2 (pt) Método de purificação da apolipoproteina a-1
ZA202000961B (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
BR112021023542A2 (pt) Métodos para purificar anticorpos
EA201491564A1 (ru) Осаждение фракции i-iv-1 иммуноглобулинов из плазмы
EP4349853A3 (en) Novel triple-helical polypeptides lacking binding affinity for the fc domain of immunoglobulin and uses thereof
BR112021020204A2 (pt) Método para purificar anticorpo com região fc modificada
ATE529433T1 (de) Verfahren zur reinigung eines il-18-bindenden proteins